Clinical Trials Logo
  1. Home
  2. Breast Cancer
  3. NCT04603183

ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL — ABIGAIL  

Breast Cancer Metastatic Clinical Trial

Official title:
A Randomized, 2-Arm, Open-Label, Ph-II Study of Abemaciclib Combined With ET w/ or w/o CT With Paclitaxel as 1L in Patients With Unresectable Locally Advanced or Metastatic HR(+)/HER2(-) BC With Aggressive Disease Criteria

Clinical Trial Summary

This is a multicenter, randomized, 2 arm, open label, phase II study. It is designed to compare the efficacy and safety of abemaciclib combined with ET (letrozole or fulvestrant) versus a short course with induction chemotherapy with paclitaxel followed by maintenance therapy with abemaciclib combined with ET (letrozole or fulvestrant) in patients with previously untreated, unresectable locally advanced, or metastatic HR positive/HER2 negative breast cancer with aggressive disease criteria.

Clinical Trial Description

The ABIGAIL study aims to provide consistent evidence that the combination of abemaciclib with ET -consisting of letrozole or fulvestrant-as first-line regimen is non-inferior to the optimal first-line chemotherapy -consisting of weekly paclitaxel-in terms of early ORR after the first 12 weeks of treatment in patients with HR-positive/HER2-negative ABC and at least one feature of aggressive disease associated with poor prognosis. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04603183
Study type Interventional
Source MedSIR
Contact
Status Active, not recruiting
Phase Phase 2
Start date June 2, 2021
Completion date June 30, 2025
View Details
See also
  Status Clinical Trial Phase
Terminated NCT04123704 - Sitravatinib in Metastatic Breast Cancer Phase 2
Active, not recruiting NCT04509596 - DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer Phase 1
Recruiting NCT04122469 - The Role of Stereo-tActic BoDy RadIotherApy iN Oligo-Progressive MalignanT Disease N/A
Completed NCT03045653 - Efficacy of High Dose Tamoxifen to Advanced Hormone Receptor-High Expressed Breast Cancer Phase 2
Terminated NCT03322215 - HR+/HER2- Advanced Breast Cancer and Endocrine Resistance Phase 2
Active, not recruiting NCT04059484 - Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer Phase 2
Recruiting NCT04368442 - Cohort Study of Patients With HER2-negative MBC and BRCA 1/2 Pathogenic Mutation
Terminated NCT03709082 - Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer Phase 1/Phase 2
Terminated NCT03642990 - NR in Chemo-induced Peripheral Neuropathy Phase 2
Terminated NCT01876251 - A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer Phase 1
Completed NCT04483505 - Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer. Phase 1
Recruiting NCT03086785 - Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Patients With Metastatic Her-2 Negative Breast Cancer Phase 2
Terminated NCT04197999 - A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer Phase 1
Not yet recruiting NCT06439693 - The SAPPHO Study: A Single-Arm, Phase II Study of Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer Phase 2
Not yet recruiting NCT03638765 - Dendritic Cell Therapy for Brain Metastases From Breast- or Lung Cancer Phase 1
Recruiting NCT06100874 - A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN) Phase 2
Completed NCT05609903 - Atezolizumab With Nab-paclitaxel for Patients With Triple-negative Stage IV Breast Cancer
Active, not recruiting NCT04597580 - Personalised Disease Monitoring in Metastatic Breast Cancer
Completed NCT05301530 - Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients. Phase 1
Active, not recruiting NCT03328884 - Evaluation of the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Breast Cancer Patients Phase 2